Related Experiment Video
Updated: Jul 1, 2025
08:21
Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera
Published on: May 23, 2025
228
Exploring cell-free assays for COVID-19 serosurvey
Lucia Inchauste1, Elif Nurtop1, Nadège Brisbarre1,2
1Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France.
Scientific Reports
|March 14, 2024
Summary
New cell-free assays can accurately detect SARS-CoV-2 antibodies in human plasma, offering a practical alternative to virus neutralization tests for COVID-19 serosurveys. These methods aid in monitoring population immunity without specialized laboratory requirements.
Area of Science:
- Immunology
- Virology
- Public Health
Background:
- Serosurveys are crucial for monitoring COVID-19 immunity.
- Virus neutralization tests (VNTs) are the gold standard but require specialized facilities.
- There is a need for accessible SARS-CoV-2 seroprevalence assessment methods.
Purpose of the Study:
- To evaluate cell-free methods as alternatives to VNTs for SARS-CoV-2 seroprevalence studies.
- To establish and validate novel inhibition ELISAs and Luminex-based assays.
- To compare these methods against commercial assays and the ELISA+VNT strategy.
Main Methods:
- Development of two anti-Spike RBD IgG inhibition ELISAs.
- Implementation of a Luminex xMAP microsphere assay for various SARS-CoV-2 antigens.
- Comparison with a commercial chemiluminescent immunoassay and the ELISA+VNT approach.
Main Results:
- The developed cell-free assays demonstrated comparable performance to existing methods in estimating positive and negative samples.
- These assays effectively detected anti-RBD antibodies.
- Performance was validated in cohorts with high expected prevalence.
Conclusions:
- Cell-free assays are viable alternatives for SARS-CoV-2 seroprevalence assessment.
- These methods overcome limitations associated with VNTs, enabling broader population immunity monitoring.
- The established assays facilitate accessible and reliable COVID-19 serosurveys.
